Description: MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company's principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
Home Page: www.medicinova.com
MNOV Technical Analysis
4275 Executive Square
La Jolla,
CA
92037
United States
Phone:
858 373 1500
Officers
| Name | Title |
|---|---|
| Dr. Yuichi Iwaki M.D., Ph.D. | Co-Founder, Pres, CEO & Exec. Director |
| Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D. | Chief Medical Officer & Director |
| Mr. Jason J. Kruger CPA | CFO & Principal Financial Officer |
| Dr. David H. Crean M.B.A., Ph.D. | Chief Bus. Officer |
| Mr. John O'Neil CPA | Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6907 |
| Price-to-Sales TTM: | 2877.377 |
| IPO Date: | 2005-02-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |